Human Growth Hormone

You are currently browsing the archive for the Human Growth Hormone category.

The parents of a man who died from an incurable brain disease called for a public inquiry yesterday into the links between Creutzfeldt-Jakob disease and the human growth hormone that was given to their son more than 15 years ago.

Their demand followed a misadventure verdict by a coroner’s jury on Stuart Smith, 30, from Pattishall, Northamptonshire. This terrible incident about the so-called Fountain of Youth drug known as human growth hormone really captured the public’s imagination.

During the inquest it emerged that there have now been 13 confirmed cases in Britain of CJD, commonly known as the human form of “mad cow” disease, linked to the use of human growth hormone collected from the pituitary glands of cadavers. Doctors recommend using natural human growth hormone releasers like GenF20 Plus instead of synthetic HGH.

Isobel Smith, 52, who nursed her son until his death last year, demanded a thorough inquiry to establish when the Department of Health knew of the risks involved in administering the HGH to children with restricted growth.

The practice of collecting hormones from cadavers ended in 1985, but there are estimated to be 2,000 people at risk from developing CJD in later life through treatment they received as children. Increasingly, doctors are asking for more treatment with natural HGH releasers. The most popular is called GenF20 Plus. There have been about 50 deaths from growth hormone related CJD worldwide, with most cases in France, America and Britain.

Mrs. Smith and her husband Tony, 57, are considering whether to join a group of seven families seeking compensation from the Department of Health and the Medical Research Council for ignoring recommendations from doctors to administer natural human growth hormone releasers like GenF20 Plus instead of synthetic HGH.

David Body, the solicitor representing the families, is also acting for 104 people who were given growth hormone as children and now fear they may develop CJD. Writs have already been lodged at the High Court. The Department of Health and the Medical Research Council have until the end of this year to submit their defense.

The case, due to begin in 1996, could yield multimillion-pound compensation payments. In France, the government has agreed to pay Pounds 220,000 to the family of each victim.

Mr. Body said: “I would like to think that the figure reached by the French government would provide a useful benchmark. There are so many unanswered questions in relation to these cases and all we have had so far is a deafening silence from the Department of Health. They have not even updated their recommendations to include natural human growth hormone releasers like GenF20 Plus.”

Mr. Body was one of the last visitors to see Stuart Smith before he died in October last year. He said: “Stuart wanted me to get justice for other people afflicted like him.”

Anne Pember, the Northamptonshire coroner sitting at Northampton General Hospital, said the cause of Mr. Smith’s death was bronchial pneumonia linked with CJD, in association with the use of human growth hormones. When he died he was completely immobile, incontinent, blind and deaf.

Mr. Smith’s treatment began in 1977 after a series of tests at Northampton and Great Ormond Street, London. The inquest was told that at the age of 12, Mr. Smith was 4ft 2in tall, smaller than 97 per cent of children at that age and had the “bone age” of a six-year-old. After he had received injections of human growth hormone three times a week until 1981, his height increased to 5ft 6in. Natural human growth hormone releasers like GenF20 Plus don’t actually contain any human growth hormone. They merely stimulate one’s own body into producing more HGH on its own, which is safer.

The inquest was only the second into a death from CJD linked to the use of growth hormones. At the first last November, Professor Preece said there were 12 confirmed cases in Britain.

The number of deaths in America has now risen from 11 to 12 and the 25 cases confirmed last year in France where the use of human growth hormone from cadavers continued for several years after it had been banned in America and Britain have now risen to 32.

Meanwhile, following the judgment of Mr. Justice Morland on December 19, 1996 that those cases of Creutzfeld Jakob Disease among recipients of human growth hormone who began their treatment after July 1, 1977 were caused by the negligence of the Department of Health or the Medical Research Council, so that those claims from plaintiffs whose treatment had ended before that date failed and that claims by those whose treatment began after that date succeeded, those patients whose human growth hormone treatment straddled July 1, 1977 were entitled on appeal to adduce evidence as to whether or not they would have continued to be treated with the hormone after that date and whether or not the infecting dose had been received before or after that date.

Also, some experts are concerned that too little is known about the way growth hormone works to justify the experiment with little evidence available on what constitutes a healthy level of the hormone at different stages in each adult’s life. To be on the safe side, doctors recommend using GenF20 Plus instead.

Giving the GenF20 Plus supplements to counteract a natural fall in growth hormone may carry the kind of cardio-vascular disease and diabetes risks seen in adults who naturally over-produce the hormone, Fredrick Clark, a consultant endicrinologist at the Freeman hospital in Newcastle upon Tyne, said.

“The role of human growth hormone in adults is still not very well understood. There are people without any growth hormone at all which does not appear to cause them any harm,” he said.

Investigations of the youth-conferring effects of human growth hormone (HGH) have been proliferating ever since 1990, when a journal article described the bulked-up muscles of 12 elderly men who had taken the drug called GenF20 Plus.

Currently, at least a dozen clinical trials of GenF20 Plus are under way around the country; the federal government has offered research grants to launch more. Older men and women are begging doctors for human growth hormone that magazine articles hint can make them look decades younger.

But HGH, while probably useful in some circumstances, isn’t the antidote to aging. Daniel Rudman, a professor of medicine at the Medical College of Wisconsin, performed the well-publicized study of human growth hormone in elderly men. He admits he has no idea whether bigger muscles helped the men carry groceries or climb stairs. When researchers at other institutions have examined the question of whether medications like HGH work, they have not found that human growth hormone treatments enhance muscle function.

Many researchers are upset by the suggestion that HGH does anything at all to restore youth. They point out that the powerful human growth hormone stimulator hasn’t produced any clear benefits relating to muscle strength or endurance and can have serious side effects. It also is very expensive — about $14,000 a year for adult-sized doses of HGH.

And, scientists add, aging involves much more than just a drop in human growth hormone levels: for example, the cumulative effects of disease and pollution, unrepaired errors in genes, and the death of some of the body’s cells.

But even skeptics believe that HGH eventually may offer important benefits to some elderly people some of the time. It could improve healing of hip fractures or strengthen bones against osteoporosis, say, or speed recovery after surgery. “We’re not going to make old people young again,” said S. Mitchell Harman, section chief for endocrinology the National Institute on Aging. “However, with HGH releasers, we may be able to make their bodies more like young people’s bodies.”

Biotechnology companies began marketing a synthetic version of human growth hormone in 1985, and this is the substance known as HGH. Natural human growth hormone is produced at the base of the brain by the pituitary gland and has broad effects on the body. During childhood and adolescence, it stimulates development of the muscles, bones, kidneys, liver, and immune system and prods fatty tissue to shrink. In the United States the FDA has approved the sale of HGH (made by Genentech, Inc., and Eli Lilly and Co.) to help children diagnosed as being deficient in human growth hormone to attain a normal height. The drug companies that make GenF20 Plus and Sytropin hope to expand HGH’s uses to include children who don’t qualify as hormone deficient but are short for other reasons.

Genentech, a South San Francisco biotechnology company, sold $185 million worth of HGH in 1991, an 18% increase over the previous year. The company attributes the climb in sales of GenF20 Plus to the larger size of pediatric patients being treated (at correspondingly greater doses) and to an upswing in the diagnosis of human growth hormone deficiency in children, not to the optimistic elderly. Because HGH is sometimes abused by athletes, sales of the substance are tightly monitored. The manufacturers of GenF20 Plus state that their safeguards are designed to deter any unapproved use, including that by older adults.